CLINICAL TRIALS PROFILE FOR MESNEX

All Clinical Trials for MESNEX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002816 ↗	Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	1996-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
NCT00002816 ↗	Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia	Completed	Children's Oncology Group	Phase 3	1996-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
NCT00002804 ↗	Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma	Completed	National Cancer Institute (NCI)	Phase 2	1996-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, surgery, and radiation therapy in treating children who have advanced soft tissue sarcoma.
NCT00002804 ↗	Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma	Completed	Children's Oncology Group	Phase 2	1996-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, surgery, and radiation therapy in treating children who have advanced soft tissue sarcoma.
NCT00002829 ↗	Bone Marrow Transplantation in Treating Patients With Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1994-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells, and may be an effective treatment for lymphoma. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with recurrent or residual low-grade lymphoma.
NCT00002829 ↗	Bone Marrow Transplantation in Treating Patients With Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1994-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells, and may be an effective treatment for lymphoma. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with recurrent or residual low-grade lymphoma.

Clinical Trial Conditions for MESNEX

Condition Name

Condition Name for MESNEX
Intervention	Trials
Leukemia	14
Lymphoma	12
Sarcoma	7
Acute Lymphoblastic Leukemia	7

Condition MeSH

Condition MeSH for MESNEX
Intervention	Trials
Leukemia	29
Precursor Cell Lymphoblastic Leukemia-Lymphoma	26
Leukemia, Lymphoid	24
Lymphoma	16

Clinical Trial Locations for MESNEX

Trials by Country

+

−

Trials by Country for MESNEX
Location	Trials
United States	447
Canada	48
Australia	15
Puerto Rico	6
Poland	6

Trials by US State

+

−

Trials by US State for MESNEX
Location	Trials
Texas	46
Tennessee	20
Illinois	20
New York	16
California	14

Clinical Trial Progress for MESNEX

Clinical Trial Phase

Clinical Trial Phase for MESNEX
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	7
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for MESNEX
Clinical Trial Phase	Trials
Completed	33
Terminated	22
Recruiting	22

Clinical Trial Sponsors for MESNEX

Sponsor Name

Sponsor Name for MESNEX
Sponsor	Trials
M.D. Anderson Cancer Center	30
National Cancer Institute (NCI)	23
Children's Oncology Group	10

Sponsor Type

Sponsor Type for MESNEX
Sponsor	Trials
Other	108
NIH	25
Industry	22

MESNEX (Mesna): Clinical Trials, Market Analysis, and Projections

Introduction to MESNEX (Mesna)

MESNEX, commonly known as mesna, is a thiol compound used primarily to prevent hemorrhagic cystitis, a potentially severe side effect of certain chemotherapy drugs like ifosfamide and high-dose cyclophosphamide. Here, we will delve into the current clinical trials, market analysis, and future projections for this crucial drug.

Clinical Trials and Efficacy

Current and Past Trials

Mesna has been extensively studied in various clinical trials to assess its efficacy and safety. For instance, a phase II trial involving patients with recurring lymphoma who had previously received cytarabine/platinum but did not respond, showed that the MINE regimen (mesna/ifosfamide, mitoxantrone, and etoposide) induced responses in a moderate fraction of patients. The trial reported a 48% response rate, with 21% achieving a complete response and 27% a partial response[1].

Another significant trial involved patients with advanced sarcoma who received the MAID regimen (mesna, doxorubicin, ifosfamide, and dacarbazine). This trial demonstrated a 47% overall response rate, with 10% of patients achieving a complete response. The median survival was 16 months, and most responses were observed within two cycles[3].

Ongoing and Future Trials

Mesna continues to be a subject of interest in ongoing clinical trials. The National Cancer Institute (NCI) lists several trials that are currently accepting patients, focusing on the use of mesna in conjunction with various chemotherapy regimens to prevent hemorrhagic cystitis and other side effects[4].

Market Analysis

Market Size and Growth

The global mesna market is anticipated to grow significantly over the forecast period (2021-2028). This growth is driven by an increase in cancer incidence and the rising use of chemotherapy. In 2018, cancer cases were estimated to be 1,735,350, and this number is expected to rise by 3% annually. As chemotherapy evolves and progresses, the demand for mesna is increasing[2][5].

Market Segmentation

The mesna market is segmented by product type, application, and geography.

By Product Type

• Oral: Oral mesna doses must be doubled compared to IV doses due to bioavailability issues. However, oral preparations allow patients to leave the hospital sooner[5].
• Injections: IV mesna is administered at specific intervals after chemotherapy to prevent hemorrhagic cystitis[2].

By Application

• Hospital Pharmacies: These are primary points of distribution for mesna, especially for patients undergoing chemotherapy.
• Retail Pharmacies: Retail pharmacies hold a significant share of the market, with a trend towards incorporating more technology and services like telemedicine and point-of-care diagnostics[5].
• Online Pharmacies: Online pharmacies are also gaining traction, offering convenience and accessibility to patients.

By Geography

• North America: Expected to hold the largest share during the forecast period due to the high incidence of cancer and advanced chemotherapy practices.
• Europe: Significant market share driven by the increasing use of chemotherapy and clinical trials.
• Asia Pacific: Rapidly growing due to increasing cancer cases and expanding healthcare infrastructure.
• Rest of the World: Includes Latin America, Middle East, and Africa, where the market is also growing but at a slower pace[5].

Competitive Landscape

The mesna market is competitive, with key players including:

• Sagent Pharmaceuticals
• Fresenius SE & Co. KGaA
• Baxter International Inc.
• Athenex Pharmaceuticals
• Mylan

These companies are focusing on product development, market expansion, and strategic partnerships to maintain their market positions[2][5].

Market Projections

Growth Drivers

• Increasing Cancer Incidence: The rising number of cancer cases globally is a primary driver for the mesna market.
• Advancements in Chemotherapy: The evolution and rapid progress in chemotherapy practices are increasing the demand for mesna.
• Clinical Trials and Approvals: Ongoing clinical research and FDA approvals for new therapies are expected to open new avenues for mesna[2][5].

Challenges and Opportunities

• Side Effects and Toxicity: While mesna is effective in preventing hemorrhagic cystitis, it can have side effects such as myelosuppression and other toxicities, which need to be managed carefully[1][3].
• Technological Advancements: The integration of technology in pharmacies and healthcare services presents opportunities for improved patient care and market growth.
• Geographical Expansion: Emerging markets in Asia Pacific and other regions offer significant growth opportunities for mesna manufacturers.

Key Takeaways

• Clinical Efficacy: Mesna has proven efficacy in preventing hemorrhagic cystitis in patients undergoing chemotherapy.
• Market Growth: The global mesna market is expected to grow significantly due to increasing cancer incidence and advancements in chemotherapy.
• Segmentation: The market is segmented by product type, application, and geography, with North America expected to hold the largest share.
• Competitive Landscape: Key players are focusing on product development and market expansion to maintain their positions.

FAQs

What is MESNEX (mesna) used for?

MESNEX (mesna) is used to prevent hemorrhagic cystitis, a side effect of certain chemotherapy drugs like ifosfamide and high-dose cyclophosphamide[4].

How is MESNEX administered?

MESNEX can be administered either as an injection into the veins or as oral tablets, typically at specific intervals after chemotherapy[2][5].

What are the common side effects of MESNEX?

Common side effects include myelosuppression, anorexia, vomiting, and in rare cases, severe mucositis and renal failure[1][3].

Which regions are expected to drive the growth of the MESNEX market?

North America, Europe, and the Asia Pacific are expected to be the key regions driving the growth of the MESNEX market due to high cancer incidence and advanced chemotherapy practices[5].

Who are the major players in the MESNEX market?

Major players include Sagent Pharmaceuticals, Fresenius SE & Co. KGaA, Baxter International Inc., Athenex Pharmaceuticals, and Mylan[2][5].

Sources

1. PubMed: A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for recurring lymphoma.
2. OMR Global: Global Mesna (Mesnex) Market 2021 Size, Growth Analysis Report.
3. PubMed: Response to mesna, doxorubicin, ifosfamide, and dacarbazine in advanced sarcoma.
4. National Cancer Institute: Mesna - NCI.
5. Verified Market Research: Mesna (Mesnex) Market Size, Share, Trends, Opportunities & Forecast.